The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure.
In a prospective trial, the immediate and long-term haematological effects of amrinone were studied in sixteen patients with refractory cardiac failure. The platelet count was significantly and variably reduced in all patients and the reduction was related to log plasma amrinone concentration. Platelet survival was significantly reduced in those cases studied. No evidence of disseminated intravascular coagulation or intravascular platelet deposition was observed and the reduced platelet survival was not considered to be the result of an immunological process. Evidence of a marrow response to the reduced platelet count and survival was seen. Although no haemorrhagic symptoms were observed in the patients, the haematological side-effects were considered to be of such severity as to limit the use of this drug in clinical practice.
D000328:Adult; D000368:Aged; D000631:Aminopyridines / Q000009:adverse effects* / Q000097:blood; D000676:Amrinone; D001792:Blood Platelets / Q000187:drug effects*; D002316:Cardiotonic Agents / Q000009:adverse effects*; D002470:Cell Survival / Q000187:drug effects; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011446:Prospective Studies
D000631:Aminopyridines; D002316:Cardiotonic Agents; D000676:Amrinone